Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D. De Carvalho
MA27.03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population
Archivos de Bronconeumologia
Pulmonary
Respiratory Medicine
Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.13-26 Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated With First-Line TKI
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Upfront Radiation Versus EGFR-TKI: Which Is the Best Approach for EGFR-mutated NSCLC Patients With Brain Metastasis?
Translational Cancer Research
Cancer Research
Oncology
Radiology
Nuclear Medicine
Imaging
Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
Expert Review of Anticancer Therapy
Oncology
Pharmacology
MALDI Mass Spectrometry Imaging of Erlotinib Administered in Combination With Bevacizumab in Xenograft Mice Bearing B901L, EGFR-mutated NSCLC Cells
Scientific Reports
Multidisciplinary
MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC
Lung Cancer Management
